放疗增敏剂在老年食管癌放疗中的疗效评价

目的分析放疗增敏剂在老年食管癌放疗中的疗效及不良反应。方法随机将74例不能或拒绝手术的食管癌患者分为单纯放疗组及放疗加增敏剂组。放疗均采用三维适形放疗,靶区剂量60～66GY,放疗增敏组每周3次于放疗前半小时内静点甘氨双唑1.25g。结果单放组完全缓解（CR）11例,部分缓解（PR）11例,稳定（NR）及进展（PD）15例,有效率为59.5%（22/37）;增放组完全缓解（CR）20例,部分缓解（PR）10例,稳定（NR）及进展（PD）7例,有效率为81.1%（30/37）。单放组及增放组1、2、3年生存率分别为40.5%（15/37）、18.9%（7/37）、5.4%（2/37）及70.3%（26/37）、40.5%（15/37）、29.7%（11/37）。两组生存率比较,差异有统计学意义（P〈0.01）。静点增敏剂后无明显不良反应。结论对于那些不能手术,或因多种原因拒绝手术的老年食管癌患者,加增敏剂放疗是其一种行之有效的方法 ,且无明显不良反应,其远期疗效尚有待进一步研究。

Curative effect evaluation of radiation sensitizing agents in elderly patients with esophageal carcinoma treated by radiotherapy

Objective To analyze the efficacy and side effects of radiation sensitizing agents in elderly patients with esophageal carcinoma treated by radiotherapy.Methods A retrospective review was carried out in 74 cases with esophageal cancer fail or refuse to operation were randomly divided into pure radiotherapy and radiotherapy sensitizer group.All patients were given three-dimensional conformal radiotherapy,and the target dose was 60-66 GY.Radiotherapy group was given glycididazole 1.25 g intravenous within half an hour before treatment 3 times a week.Results In radiation group,11 cases were complete response （CR）,11 cases were partial response （PR）,15 cases were no response or progressive disease （NR＋PD）,with an efficiency of 59.5% （22/37）.In sensitizer group,20 cases were complete response （CR）,10 cases were partial response （PR）,7 cases were no response or progressive disease （NR＋PD）,with an efficiency of 81.1% （30/37）.1,2,3 years survival rates of radiation group and sensitizer group were 40.5% （15/37）,18.9% （7/37）,5.4% （2/37） and 70.3% （26/37）,40.5% （15/37）,29.7% （11/37） respectively.There was no obvious adverse reaction in sensitizer group.Conclusion Radiotherapy adds sensitizing agents is effective for patients with esophageal carcinoma who fail or refuse to accept surgery.It has no obvious adverse reaction,but its long-term efficacy remains to be further studied.